Extension of Designation of Scarce Materials or Threatened Materials Subject to COVID-19 Hoarding Prevention Measures; Correction of Extension Date, 83975 [2020-28374]
Download as PDF
Federal Register / Vol. 85, No. 247 / Wednesday, December 23, 2020 / Notices
Application No.
NDA
NDA
NDA
NDA
019916
020593
020634
021241
.............
.............
.............
.............
NDA 206544 .............
NDA 208399 .............
Drug
Applicant
Morphine Sulfate Injection, 1 mg/mL and 5 mg/mL .............................................
Depacon (valproate sodium) Injection, Equivalent to (EQ) 100 mg base/mL ......
Levaquin (levofloxacin) Tablets, 250 mg, 500 mg, and 750 mg ..........................
Ortho Tri-Cyclen Lo (ethinyl estradiol and norgestimate) Oral-28 (White) Tablets, 0.025 mg ethinyl estradiol and 0.18 mg norgestimate; (Light Blue) Tablets, 0.025 mg ethinyl estradiol and 0.215 mg norgestimate; (Dark Blue) Tablets, 0.025 mg ethinyl estradiol and 0.250 mg norgestimate.
MorphaBond ER (morphine sulfate) Extended-Release Tablets, 15 mg, 30 mg,
60 mg, and 100 mg.
Varubi (rolapitant HCl) Injectable Emulsion, EQ 166.5 mg base/92.5 mL (EQ
1.8 mg base/mL).
NDA 209203 .............
Duzallo (allopurinol and lesinurad) Tablets, 200 mg/200 mg and 300 mg/200
mg.
NDA 210895 .............
Welchol (colesevelam HCl) Chewable Bars, 3.75 g ............................................
Therefore, approval of the
applications listed in the table, and all
amendments and supplements thereto,
is hereby withdrawn as of January 22,
2021. Approval of each entire
application is withdrawn, including any
strengths and dosage forms
inadvertently missing from the table.
Introduction or delivery for introduction
into interstate commerce of products
without approved new drug
applications violates section 301(a) and
(d) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 331(a) and (d)).
Drug products that are listed in the table
that are in inventory on January 22,
2021 may continue to be dispensed
until the inventories have been depleted
or the drug products have reached their
expiration dates or otherwise become
violative, whichever occurs first.
Dated: December 16, 2020.
Lauren K. Roth,
Acting Principal Associate Commissioner for
Policy.
[FR Doc. 2020–28346 Filed 12–22–20; 8:45 am]
BILLING CODE 4164–01–P
revising the last sentence in the
‘‘Summary’’ section.
FOR FURTHER INFORMATION CONTACT:
Paige Ezernack, Office of the Assistant
Secretary for Preparedness and
Response, Office of Strategy, Policy,
Planning, and Requirements, Suite
5440—O’Neill House Office Building,
200 C Street SW, Washington, DC
20201, (202) 260–0365.
SUPPLEMENTARY INFORMATION:
I. Correction of Errors
In FR Doc. 2020–16458 of July 30,
2020 (85 FR 45895–45897), make the
following corrections:
On page 48596, first full column,
SUMMARY section, change second to last
sentence to ‘‘This notice, issued on July
23, 2020, extends the March 25
Designation Notice to January 19, 2021.’’
The expiration date, January 19, 2021 is
not 120 days from the date of issuance
so remove that reference.
Wilma Robinson,
Deputy Executive Secretary, Department of
Health and Human Services.
[FR Doc. 2020–28374 Filed 12–22–20; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4150–28–P
Office of the Secretary
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Extension of Designation of Scarce
Materials or Threatened Materials
Subject to COVID–19 Hoarding
Prevention Measures; Correction of
Extension Date
Office of the Secretary (OS),
DHHS.
ACTION: Correction.
jbell on DSKJLSW7X2PROD with NOTICES
AGENCY:
SUMMARY: This document updates the
July 30, 2020, Federal Register Notice
entitled ‘‘Extension of Designation of
Scarce Materials or Threatened
Materials Subject to COVID–19
Hoarding Prevention Measures,’’ by
VerDate Sep<11>2014
21:21 Dec 22, 2020
Jkt 253001
National Institutes of Health
National Institute of Dental &
Craniofacial Research; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory Dental
and Craniofacial Research Council.
The meeting will be open to the
public via NIH videocast. The URL link
to this meeting is https://
videocast.nih.gov/watch=38984.
PO 00000
Frm 00093
Fmt 4703
83975
Sfmt 4703
Do.
AbbVie, Inc.
Janssen Pharmaceuticals, Inc.
Do.
Daiichi Sankyo, Inc., 211 Mount Airy
Rd., Basking Ridge, NJ 07920.
TerSera Therapeutics LLC, 520 Lake
Cook Rd., suite 500, Deerfield, IL
60015.
Ironwood Pharmaceuticals, Inc., 100
Summer St., suite 2300, Boston, MA
02110.
Daiichi Sankyo, Inc.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Dental and Craniofacial Research Council.
Date: January 27, 2021.
Open: 10:00 a.m. to 1:05 p.m.
Agenda: Report of the Director, NIDCR
Place: National Institute of Dental and
Craniofacial Research, National Institutes of
Health, 6701 Democracy Boulevard, Room
662 Bethesda, MD 20892, (Virtual Meeting).
Closed: 1:20 p.m. to 2:00 p.m.
Agenda: Grant applications.
Place: National Institute of Dental and
Craniofacial Research, National Institutes of
Health, 6701 Democracy Boulevard, Room
662 Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Alicia J. Dombroski, Ph.D.,
Director, Division of Extramural Activities,
National Institute of Dental and Craniofacial
Research, National Institutes of Health, 6701
Democracy Boulevard, Room 662, Bethesda,
MD 20892, 301–594–4805, adombroski@
nidcr.nih.gov.
Any interested person may file written
comments with the committee no later than
15 days after the meeting by forwarding the
statement to the Contact Person listed on this
notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nidcr.nih.gov/about, where an agenda
and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
E:\FR\FM\23DEN1.SGM
23DEN1
Agencies
[Federal Register Volume 85, Number 247 (Wednesday, December 23, 2020)]
[Notices]
[Page 83975]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-28374]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Extension of Designation of Scarce Materials or Threatened
Materials Subject to COVID-19 Hoarding Prevention Measures; Correction
of Extension Date
AGENCY: Office of the Secretary (OS), DHHS.
ACTION: Correction.
-----------------------------------------------------------------------
SUMMARY: This document updates the July 30, 2020, Federal Register
Notice entitled ``Extension of Designation of Scarce Materials or
Threatened Materials Subject to COVID-19 Hoarding Prevention
Measures,'' by revising the last sentence in the ``Summary'' section.
FOR FURTHER INFORMATION CONTACT: Paige Ezernack, Office of the
Assistant Secretary for Preparedness and Response, Office of Strategy,
Policy, Planning, and Requirements, Suite 5440--O'Neill House Office
Building, 200 C Street SW, Washington, DC 20201, (202) 260-0365.
SUPPLEMENTARY INFORMATION:
I. Correction of Errors
In FR Doc. 2020-16458 of July 30, 2020 (85 FR 45895-45897), make
the following corrections:
On page 48596, first full column, SUMMARY section, change second to
last sentence to ``This notice, issued on July 23, 2020, extends the
March 25 Designation Notice to January 19, 2021.'' The expiration date,
January 19, 2021 is not 120 days from the date of issuance so remove
that reference.
Wilma Robinson,
Deputy Executive Secretary, Department of Health and Human Services.
[FR Doc. 2020-28374 Filed 12-22-20; 8:45 am]
BILLING CODE 4150-28-P